ALVAL.PA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 18:35):

Stats
Dzisiejszy wolumen	49 465.00
Średni wolumen	29 937.00
Kapitalizacja rynkowa	64.85M
EPS	€0 ( 2024-04-28 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-6.97
ATR14	€0.0150 (0.37%)

Wolumen Korelacja

Długi: -0.03 (neutral)

Krótki: 0.33 (neutral)

Signal:(47.568) Neutral

Valbiotis SA Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Valbiotis SA Korelacja - Waluta/Towar

0.84
( strong )

0.80
( moderate )

0.00
( neutral )

0.64
( weak )

0.52
( weak )

-0.16
( neutral )

Valbiotis SA Finanse

Annual	2023
Przychody:	€4.73M
Zysk brutto:	€2.00M (42.26 %)
EPS:	€-0.590

FY	2023
Przychody:	€4.73M
Zysk brutto:	€2.00M (42.26 %)
EPS:	€-0.590

FY	2022
Przychody:	€785 000
Zysk brutto:	€767 000 (97.71 %)
EPS:	€-1.220

FY	2021
Przychody:	€2.05M
Zysk brutto:	€1.63M (79.64 %)
EPS:	€-0.0828

Financial Reports:

No articles found.

Valbiotis SA

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.